Across 20 randomized trials, GLP-1 receptor agonists resolved liver inflammation (MASH) 3 times more often than controls, while also improving fibrosis, weight, and liver enzymes — though benefits on weight and fibrosis were limited in non-diabetic patients.
3x more likely to resolve MASHGLP-1 agonists tripled the rate of liver inflammation resolution without worsening fibrosis across 20 randomized trials
What the researchers found
GLP-1 agonists were associated with a statistically significant 3-fold increase in resolution of MASH without worsening fibrosis (RR 3.03, p<0.05) compared to controls. They also significantly improved liver fibrosis, weight loss, HbA1c, and alanine aminotransferase levels (SMD -0.54, p=0.008).
Importantly, in patients without type 2 diabetes, GLP-1 agonists showed no significant effect on weight loss (SMD -0.97, p=0.12) or fibrosis improvement (RR 1.54, p=0.24). Overall adverse events were slightly higher with GLP-1 agonists (RR 1.10, p<0.05), but serious adverse events were comparable between groups.
Why it matters
MASLD affects roughly a quarter of the global population and can progress to cirrhosis and liver cancer, yet effective pharmacological treatments have been limited. This meta-analysis provides the strongest evidence to date that GLP-1 peptide therapies can resolve liver inflammation and improve fibrosis, positioning them as a potential first-line treatment — especially for the large population of patients who have both fatty liver disease and type 2 diabetes.
How the study worked
This was a systematic review and meta-analysis of 20 randomized parallel controlled trials identified through PubMed, Scopus, and Web of Science (searched October 2025). Study quality was assessed using Cochrane ROB2. Analysis was performed in RevMan 5.4 with subgroup analyses based on diabetes status, control group type, and GLP-1 agonist class (single, dual, or triple agonists).
What this study cannot tell us
There was heterogeneity across the 20 included studies in terms of GLP-1 agonist type, dosing, treatment duration, and patient populations. The number of studies in non-diabetic patients was limited, making conclusions for that subgroup preliminary. Some outcomes had incomplete data across studies. The slightly higher overall adverse event rate needs consideration. Publication bias cannot be fully excluded. The analysis groups single, dual, and triple agonists together, which may obscure differences between drug classes.
How to read the evidence
This is a systematic review and meta-analysis of 20 randomized controlled trials — among the highest levels of evidence in medicine. The use of Cochrane ROB2 for quality assessment and subgroup analyses strengthens the findings. However, heterogeneity across studies and limited data in non-diabetic populations are notable caveats.
When this study was published
Published in 2026 with a literature search through October 2025, this is an extremely current meta-analysis capturing the latest available trial data on GLP-1 agonists for liver disease.
The bigger picture
This meta-analysis arrives at a critical moment: the first GLP-1-based drug (resmetirom is a different class, but semaglutide trials are ongoing) targeting liver disease specifically is under development, and dual/triple agonists promise even greater metabolic effects. The finding that benefits differ between diabetic and non-diabetic patients may shape how these peptide drugs are positioned in liver disease treatment guidelines.
Questions still open
- Will dual and triple GLP-1 agonists show even greater liver benefits than single agonists in head-to-head comparisons?
- Why do non-diabetic patients with fatty liver disease appear to benefit less from GLP-1 agonists, and could higher doses overcome this?
- Can GLP-1 agonists prevent progression to cirrhosis and liver cancer in long-term follow-up studies?
Common questions
Can GLP-1 medications like semaglutide treat fatty liver disease?
Do GLP-1 drugs help fatty liver disease in people who don't have diabetes?
Read the original research
The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
Pharmaceutics, 18(1)
Citation
Tornea, Denisia Adelina; Goldis, Christian; Isaic, Alexandru; Motofelea, Alexandru Catalin; Sima, Alexandra Christa; Ciocarlie, Tudor; Crintea, Andreea; Diaconescu, Razvan Gheorghe; Motofelea, Nadica; Goldis, Adrian. (2026). The Effect of GLP-1 Agonists on Patients with Metabolic-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.. Pharmaceutics, 18(1). https://doi.org/10.3390/pharmaceutics18010086